Failings Of Clinical Trials, Adaptive Pathways Dominate NGO Conference
Executive Summary
Speakers at a conference organized by Health Action International highlighted ongoing concerns over the commercial nature of clinical trials, the growing trend to conduct trials in low and middle income countries, and perceived failings of the European Medicines Agency’s adaptive pathways initiative.
You may also be interested in...
EMA Defends Adaptive Pathways Against Fresh Attack Following Pilot Report
The European Medicines Agency has dismissed a call to stop accepting applications for its adaptive pathways program until it has better evidence on how to use real-world data.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.